The global cancer stem cells market is envisioned to garner $2,711.8 million by 2031, growing from $1,055.2 million in 2021 at a CAGR of 10.0% from 2022 to 2031.
Cancers are time-related illnesses that pose a major threat to human life. For the treatment of cancer, a variety of methods have been developed, including surgery, chemo, radiation, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males, and the death rate from cancer has also decreased over the same period. Traditional cancer treatments, which only work for certain types of malignant tumors, metastasis, heterogeneity, as well as resistance to chemotherapy, radiotherapy, and avoiding immunological surveillance are the primary causes of cancer treatment failures. The traits of cancer stem cells could be the cause of all these failures. Due to their capacity to stop in the early phase, which results in the formation of fresh tumors, cancer stem cells can lead to cancer spread, cancer relapse, multidrug resistance, and radiation resistance. Cancer stem cells may therefore be considered of as the most promising cancer effective treatments.
The clinical procedures involved in stem cell transplantation are complex and high risk, including radiation therapy that is used to diagnose malignancy. Cancer stem cells (CSCs) and regular stem cells share many fundamental biologicals signaling pathways. Normal stem cells may become CSCs when their microenvironment changes negatively, which then causes the creation of the complete tumor tissue. While in culture prior to transplantation, transplanted stem cells may be exposed to environmental factors that could alter their genomic expression and future phenotype. Stem cells are more likely to become cancerous cells with increased culture time. These factors are predicted to hamper the cancer stem cells market growth in forecast time period.
Cancer stem cells are one of the causes of cancer cell relapse and metastasis. They are resistant to the majority of chemotherapeutic treatments. Additionally, cancer stem cell contributes to tumor cell heterogeneity and recurrent illness to some extent. Cancer stem cells must be addressed if total tumor regression is to be achieved. Recent developments in immunotherapies have demonstrated encouraging results in the treatment of cancer, which are also applicable to cancer stem cells. Cancer stem cells in different tumors express immunological markers and show certain immune traits, which can be exploited in immunotherapies to target cancer stem cells in the tumor microenvironment. Cancer stem cells have recently gained huge traction when it comes to technological advancements as well as research & development (R&D) initiatives. Cancer stem cells are increasingly being targeted using dendritic cell (DC)-based vaccines, adaptive T-cells, oncolytic viruses, immune checkpoint inhibitors, and combination treatments.
The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. The COVID-19 outbreak caused a significant effect on the cancer stem cell market growth. The rise in cancer cases globally is increasing the need for efficacious cancer stem cell therapies. Cancer stem cell researchers along with various government bodies are massively investing in Research and Development activities for cell-based therapies to cater to the rising demand for cancer cell therapies during the COVID-19 pandemic. For instance, during the COVID-19 pandemic, the use of stem cell applicability for resistance to the COVID-19 pandemic is researched.
The key players profiled in this report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.
Cancers are time-related illnesses that pose a major threat to human life. For the treatment of cancer, a variety of methods have been developed, including surgery, chemo, radiation, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males, and the death rate from cancer has also decreased over the same period. Traditional cancer treatments, which only work for certain types of malignant tumors, metastasis, heterogeneity, as well as resistance to chemotherapy, radiotherapy, and avoiding immunological surveillance are the primary causes of cancer treatment failures. The traits of cancer stem cells could be the cause of all these failures. Due to their capacity to stop in the early phase, which results in the formation of fresh tumors, cancer stem cells can lead to cancer spread, cancer relapse, multidrug resistance, and radiation resistance. Cancer stem cells may therefore be considered of as the most promising cancer effective treatments.
The clinical procedures involved in stem cell transplantation are complex and high risk, including radiation therapy that is used to diagnose malignancy. Cancer stem cells (CSCs) and regular stem cells share many fundamental biologicals signaling pathways. Normal stem cells may become CSCs when their microenvironment changes negatively, which then causes the creation of the complete tumor tissue. While in culture prior to transplantation, transplanted stem cells may be exposed to environmental factors that could alter their genomic expression and future phenotype. Stem cells are more likely to become cancerous cells with increased culture time. These factors are predicted to hamper the cancer stem cells market growth in forecast time period.
Cancer stem cells are one of the causes of cancer cell relapse and metastasis. They are resistant to the majority of chemotherapeutic treatments. Additionally, cancer stem cell contributes to tumor cell heterogeneity and recurrent illness to some extent. Cancer stem cells must be addressed if total tumor regression is to be achieved. Recent developments in immunotherapies have demonstrated encouraging results in the treatment of cancer, which are also applicable to cancer stem cells. Cancer stem cells in different tumors express immunological markers and show certain immune traits, which can be exploited in immunotherapies to target cancer stem cells in the tumor microenvironment. Cancer stem cells have recently gained huge traction when it comes to technological advancements as well as research & development (R&D) initiatives. Cancer stem cells are increasingly being targeted using dendritic cell (DC)-based vaccines, adaptive T-cells, oncolytic viruses, immune checkpoint inhibitors, and combination treatments.
The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. The COVID-19 outbreak caused a significant effect on the cancer stem cell market growth. The rise in cancer cases globally is increasing the need for efficacious cancer stem cell therapies. Cancer stem cell researchers along with various government bodies are massively investing in Research and Development activities for cell-based therapies to cater to the rising demand for cancer cell therapies during the COVID-19 pandemic. For instance, during the COVID-19 pandemic, the use of stem cell applicability for resistance to the COVID-19 pandemic is researched.
The key players profiled in this report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.
Key Market Segments
By Cancer Forms
- Breast
- Blood
- Lung
- Brain
- Colorectal
- Pancreatic
- Bladder
- Liver
- Others
By Application
- Trageted Cancerous Stem Cells
- Stem Cell-based cancer Therapy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest Of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- Thermo Fisher Scientific Inc.
- AbbVie Inc.
- Miltenyi Biotec
- STEMCELL Technologies Inc.
- Merck KGaA
- Stemline Therapeutics, Inc.
- MacroGenics, Inc.
- Bionomics
- FUJIFILM Irvine Scientific.
- Lineage Cell Therapeutics, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Regulatory Guidelines
3.8. Value Chain Analysis
3.9. Market Share Analysis
3.10. Key Regulation Analysis
3.11. Patent Landscape
CHAPTER 4: CANCER STEM CELLS MARKET, BY CANCER FORMS
4.1 Overview
4.1.1 Market size and forecast
4.2 Breast
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Blood
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Lung
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Brain
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Colorectal
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Pancreatic
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Bladder
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
4.9 Liver
4.9.1 Key market trends, growth factors and opportunities
4.9.2 Market size and forecast, by region
4.9.3 Market analysis by country
5.0 Others
5.0.1 Key market trends, growth factors and opportunities
5.0.2 Market size and forecast, by region
5.0.3 Market analysis by country
CHAPTER 5: CANCER STEM CELLS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Trageted CanceroU.S.em Cells
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Stem Cell-based cancer Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: CANCER STEM CELLS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Cancer Forms
6.2.3 North America Market size and forecast, by Application
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Cancer Forms
6.2.4.1.2 Market size and forecast, by Application
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Cancer Forms
6.2.4.2.2 Market size and forecast, by Application
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Cancer Forms
6.2.4.3.2 Market size and forecast, by Application
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Cancer Forms
6.3.3 Europe Market size and forecast, by Application
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Cancer Forms
6.3.4.1.2 Market size and forecast, by Application
6.3.4.2 United Kingdom
6.3.4.2.1 Market size and forecast, by Cancer Forms
6.3.4.2.2 Market size and forecast, by Application
6.3.4.3 France
6.3.4.3.1 Market size and forecast, by Cancer Forms
6.3.4.3.2 Market size and forecast, by Application
6.3.4.4 Spain
6.3.4.4.1 Market size and forecast, by Cancer Forms
6.3.4.4.2 Market size and forecast, by Application
6.3.4.5 Italy
6.3.4.5.1 Market size and forecast, by Cancer Forms
6.3.4.5.2 Market size and forecast, by Application
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Cancer Forms
6.3.4.6.2 Market size and forecast, by Application
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Cancer Forms
6.4.3 Asia-Pacific Market size and forecast, by Application
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Cancer Forms
6.4.4.1.2 Market size and forecast, by Application
6.4.4.2 Japan
6.4.4.2.1 Market size and forecast, by Cancer Forms
6.4.4.2.2 Market size and forecast, by Application
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Cancer Forms
6.4.4.3.2 Market size and forecast, by Application
6.4.4.4 South Korea
6.4.4.4.1 Market size and forecast, by Cancer Forms
6.4.4.4.2 Market size and forecast, by Application
6.4.4.5 Australia
6.4.4.5.1 Market size and forecast, by Cancer Forms
6.4.4.5.2 Market size and forecast, by Application
6.4.4.6 Rest Of Asia Pacific
6.4.4.6.1 Market size and forecast, by Cancer Forms
6.4.4.6.2 Market size and forecast, by Application
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Cancer Forms
6.5.3 LAMEA Market size and forecast, by Application
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Cancer Forms
6.5.4.1.2 Market size and forecast, by Application
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Cancer Forms
6.5.4.2.2 Market size and forecast, by Application
6.5.4.3 UAE
6.5.4.3.1 Market size and forecast, by Cancer Forms
6.5.4.3.2 Market size and forecast, by Application
6.5.4.4 South Africa
6.5.4.4.1 Market size and forecast, by Cancer Forms
6.5.4.4.2 Market size and forecast, by Application
6.5.4.5 Rest of LAMEA
6.5.4.5.1 Market size and forecast, by Cancer Forms
6.5.4.5.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Thermo Fisher Scientific Inc.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 AbbVie Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Miltenyi Biotec
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 STEMCELL Technologies Inc.
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Merck KGaA
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Stemline Therapeutics, Inc.
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 MacroGenics, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Bionomics
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 FUJIFILM Irvine Scientific.
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Lineage Cell Therapeutics, Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
List of Tables
Table 1. Global Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 2. Cancer Stem Cells Market Size, for Breast, by Region, 2021-2031 ($Million)
Table 3. Cancer Stem Cells Market for Breast, by Country, 2021-2031 ($Million)
Table 4. Cancer Stem Cells Market Size, for Blood, by Region, 2021-2031 ($Million)
Table 5. Cancer Stem Cells Market for Blood, by Country, 2021-2031 ($Million)
Table 6. Cancer Stem Cells Market Size, for Lung, by Region, 2021-2031 ($Million)
Table 7. Cancer Stem Cells Market for Lung, by Country, 2021-2031 ($Million)
Table 8. Cancer Stem Cells Market Size, for Brain, by Region, 2021-2031 ($Million)
Table 9. Cancer Stem Cells Market for Brain, by Country, 2021-2031 ($Million)
Table 10. Cancer Stem Cells Market Size, for Colorectal, by Region, 2021-2031 ($Million)
Table 11. Cancer Stem Cells Market for Colorectal, by Country, 2021-2031 ($Million)
Table 12. Cancer Stem Cells Market Size, for Pancreatic, by Region, 2021-2031 ($Million)
Table 13. Cancer Stem Cells Market for Pancreatic, by Country, 2021-2031 ($Million)
Table 14. Cancer Stem Cells Market Size, for Bladder, by Region, 2021-2031 ($Million)
Table 15. Cancer Stem Cells Market for Bladder, by Country, 2021-2031 ($Million)
Table 16. Cancer Stem Cells Market Size, for Liver, by Region, 2021-2031 ($Million)
Table 17. Cancer Stem Cells Market for Liver, by Country, 2021-2031 ($Million)
Table 18. Cancer Stem Cells Market Size, for Others, by Region, 2021-2031 ($Million)
Table 19. Cancer Stem Cells Market for Others, by Country, 2021-2031 ($Million)
Table 20. Global Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 21. Cancer Stem Cells Market Size, for Trageted CanceroU.S.em Cells, by Region, 2021-2031 ($Million)
Table 22. Cancer Stem Cells Market for Trageted CanceroU.S.em Cells, by Country, 2021-2031 ($Million)
Table 23. Cancer Stem Cells Market Size, for Stem Cell-based Cancer Therapy, by Region, 2021-2031 ($Million)
Table 24. Cancer Stem Cells Market for Stem Cell-based Cancer Therapy, by Country, 2021-2031 ($Million)
Table 25. Cancer Stem Cells Market, by Region, 2021-2031 ($Million)
Table 26. North America Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 27. North America Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 28. North America Cancer Stem Cells Market, by Country, 2021-2031 ($Million)
Table 29. U.S. Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 30. U.S. Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 31. Canada Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 32. Canada Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 33. Mexico Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 34. Mexico Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 35. Europe Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 36. Europe Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 37. Europe Cancer Stem Cells Market, by Country, 2021-2031 ($Million)
Table 38. Germany Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 39. Germany Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 40. United Kingdom Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 41. United Kingdom Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 42. France Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 43. France Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 44. Spain Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 45. Spain Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 46. Italy Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 47. Italy Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 48. Rest of Europe Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 49. Rest of Europe Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 50. Asia-Pacific Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 51. Asia-Pacific Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 52. Asia-Pacific Cancer Stem Cells Market, by Country, 2021-2031 ($Million)
Table 53. China Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 54. China Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 55. Japan Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 56. Japan Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 57. India Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 58. India Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 59. South Korea Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 60. South Korea Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 61. Australia Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 62. Australia Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 63. Rest of Asia-Pacific Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 64. Rest of Asia-Pacific Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 65. LAMEA Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 66. LAMEA Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 67. LAMEA Cancer Stem Cells Market, by Country, 2021-2031 ($Million)
Table 68. Brazil Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 69. Brazil Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 70. Saudi Arabia Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 71. Saudi Arabia Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 72. UAE Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 73. UAE Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 74. South Africa Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 75. South Africa Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 76. Rest of LAMEA Cancer Stem Cells Market, by Cancer Forms, 2021-2031 ($Million)
Table 77. Rest of LAMEA Cancer Stem Cells Market, by Application, 2021-2031 ($Million)
Table 78. Thermo Fisher Scientific Inc.: Company Snapshot
Table 79. Thermo Fisher Scientific Inc.: Operating Segments
Table 80. Thermo Fisher Scientific Inc.: Product Portfolio
Table 81. Thermo Fisher Scientific Inc.: Net Sales
Table 82. Thermo Fisher Scientific Inc.: Key Strategies
Table 83. Abbvie Inc.: Company Snapshot
Table 84. Abbvie Inc.: Operating Segments
Table 85. Abbvie Inc.: Product Portfolio
Table 86. Abbvie Inc.: Net Sales
Table 87. Abbvie Inc.: Key Strategies
Table 88. Miltenyi Biotec: Company Snapshot
Table 89. Miltenyi Biotec: Operating Segments
Table 90. Miltenyi Biotec: Product Portfolio
Table 91. Miltenyi Biotec: Net Sales
Table 92. Miltenyi Biotec: Key Strategies
Table 93. Stemcell Technologies Inc.: Company Snapshot
Table 94. Stemcell Technologies Inc.: Operating Segments
Table 95. Stemcell Technologies Inc.: Product Portfolio
Table 96. Stemcell Technologies Inc.: Net Sales
Table 97. Stemcell Technologies Inc.: Key Strategies
Table 98. Merck KGaA: Company Snapshot
Table 99. Merck KGaA: Operating Segments
Table 100. Merck KGaA: Product Portfolio
Table 101. Merck KGaA: Net Sales
Table 102. Merck KGaA: Key Strategies
Table 103. Stemline Therapeutics, Inc.: Company Snapshot
Table 104. Stemline Therapeutics, Inc.: Operating Segments
Table 105. Stemline Therapeutics, Inc.: Product Portfolio
Table 106. Stemline Therapeutics, Inc.: Net Sales
Table 107. Stemline Therapeutics, Inc.: Key Strategies
Table 108. Macrogenics, Inc.: Company Snapshot
Table 109. Macrogenics, Inc.: Operating Segments
Table 110. Macrogenics, Inc.: Product Portfolio
Table 111. Macrogenics, Inc.: Net Sales
Table 112. Macrogenics, Inc.: Key Strategies
Table 113. Bionomics: Company Snapshot
Table 114. Bionomics: Operating Segments
Table 115. Bionomics: Product Portfolio
Table 116. Bionomics: Net Sales
Table 117. Bionomics: Key Strategies
Table 118. Fujifilm Irvine Scientific.: Company Snapshot
Table 119. Fujifilm Irvine Scientific.: Operating Segments
Table 120. Fujifilm Irvine Scientific.: Product Portfolio
Table 121. Fujifilm Irvine Scientific.: Net Sales
Table 122. Fujifilm Irvine Scientific.: Key Strategies
Table 123. Lineage Cell Therapeutics, Inc.: Company Snapshot
Table 124. Lineage Cell Therapeutics, Inc.: Operating Segments
Table 125. Lineage Cell Therapeutics, Inc.: Product Portfolio
Table 126. Lineage Cell Therapeutics, Inc.: Net Sales
Table 127. Lineage Cell Therapeutics, Inc.: Key Strategies
List of Figures
Figure 1. Cancer Stem Cells Market Segmentation
Figure 2. Cancer Stem Cells Market, 2021-2031
Figure 3. Cancer Stem Cells Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Cancer Stem Cells Mark.:Drivers, Restraints and Opportunities
Figure 12. Regulatory Guidelines
Figure 13. Value Chain Analysis
Figure 14. Market Share Analysis
Figure 15. Key Regulation Analysis
Figure 16. Patent Analysis by Company
Figure 17. Patent Analysis by Country
Figure 18. Cancer Stem Cells Market, By Cancer Forms, 2021(%)
Figure 19. Comparative Share Analysis of Breast Cancer Stem Cells Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Blood Cancer Stem Cells Market, 2021-2031(%)
Figure 21. Comparative Share Analysis of Lung Cancer Stem Cells Market, 2021-2031(%)
Figure 22. Comparative Share Analysis of Brain Cancer Stem Cells Market, 2021-2031(%)
Figure 23. Comparative Share Analysis of Colorectal Cancer Stem Cells Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Pancreatic Cancer Stem Cells Market, 2021-2031(%)
Figure 25. Comparative Share Analysis of Bladder Cancer Stem Cells Market, 2021-2031(%)
Figure 26. Comparative Share Analysis of Liver Cancer Stem Cells Market, 2021-2031(%)
Figure 27. Comparative Share Analysis of Others Cancer Stem Cells Market, 2021-2031(%)
Figure 28. Cancer Stem Cells Market, By Application, 2021(%)
Figure 29. Comparative Share Analysis of Trageted Cancerous Stem Cells Cancer Stem Cells Market, 2021-2031(%)
Figure 30. Comparative Share Analysis of Stem Cell-Based Cancer Therapy Cancer Stem Cells Market, 2021-2031(%)
Figure 31. Cancer Stem Cells Market by Region, 2021
Figure 32. U.S. Cancer Stem Cells Market, 2021-2031($Million)
Figure 33. Canada Cancer Stem Cells Market, 2021-2031($Million)
Figure 34. Mexico Cancer Stem Cells Market, 2021-2031($Million)
Figure 35. Germany Cancer Stem Cells Market, 2021-2031($Million)
Figure 36. United Kingdom Cancer Stem Cells Market, 2021-2031($Million)
Figure 37. France Cancer Stem Cells Market, 2021-2031($Million)
Figure 38. Spain Cancer Stem Cells Market, 2021-2031($Million)
Figure 39. Italy Cancer Stem Cells Market, 2021-2031($Million)
Figure 40. Rest of Europe Cancer Stem Cells Market, 2021-2031($Million)
Figure 41. China Cancer Stem Cells Market, 2021-2031($Million)
Figure 42. Japan Cancer Stem Cells Market, 2021-2031($Million)
Figure 43. India Cancer Stem Cells Market, 2021-2031($Million)
Figure 44. South Korea Cancer Stem Cells Market, 2021-2031($Million)
Figure 45. Australia Cancer Stem Cells Market, 2021-2031($Million)
Figure 46. Rest of Asia-Pacific Cancer Stem Cells Market, 2021-2031($Million)
Figure 47. Brazil Cancer Stem Cells Market, 2021-2031($Million)
Figure 48. Saudi Arabia Cancer Stem Cells Market, 2021-2031($Million)
Figure 49. Uae Cancer Stem Cells Market, 2021-2031($Million)
Figure 50. South Africa Cancer Stem Cells Market, 2021-2031($Million)
Figure 51. Rest of LAMEA Cancer Stem Cells Market, 2021-2031($Million)
Figure 52. Top Winning Strategies, by Year
Figure 53. Top Winning Strategies, by Development
Figure 54. Top Winning Strategies, by Company
Figure 55. Product Mapping of Top 10 Players
Figure 56. Competitive Dashboard
Figure 57. Competitive Heatmap of Top 10 Key Players
Figure 58. Thermo Fisher Scientific Inc.: Net Sales, ($Million)
Figure 59. Abbvie Inc.: Net Sales, ($Million)
Figure 60. Miltenyi Biote.: Net Sales, ($Million)
Figure 61. Stemcell Technologies Inc.: Net Sales, ($Million)
Figure 62. Merck Kga.: Net Sales, ($Million)
Figure 63. Stemline Therapeutics, Inc.: Net Sales, ($Million)
Figure 64. Macrogenics, Inc.: Net Sales, ($Million)
Figure 65. Bionomic.: Net Sales, ($Million)
Figure 66. Fujifilm Irvine Scientific.: Net Sales, ($Million)
Figure 67. Lineage Cell Therapeutics, Inc.: Net Sales, ($Million)
Executive Summary
According to the report, “Cancer Stem Cells Market," the cancer stem cells market size was $1.1 billion in 2021, and is estimated to reach $2.7 billion by 2031, growing at a CAGR of 10% from 2022 to 2031.Cancer develops when abnormal cells in a particular area of the body divide uncontrollably. Specialized human cells known as stem cells have a number of distinguishing traits, including the ability to identify cancer cells, produce a variety of bioactive compounds, and inhibit the immune system, all of which increase tumor targeting and aid in the treatment of various types of cancer. Owing to these characteristics, cancer stem cells therapy is more effective compared to other gene therapies. Preclinical stem cell technologies have recently demonstrated promise for use in individualized cancer treatment. The cancer stem cell-focused therapeutic gain is expected to be applied in tailored cancer stem cell therapy which is a major factor estimated to propel the cancer stem cells market size in the upcoming years.
However, the market for cancer stem cells is limited by strict healthcare agency regulations and the high cost of stem cell therapy treatments. Because stem cell therapies are generally experimental and are not usually covered by health insurance policies or government-sponsored incentives, no significant insurance companies now offer coverage for them. These factors are anticipated to restrict the cancer stem cells market advancements in the upcoming years.
Stem cell technology has the potential to revolutionize cancer treatment. The delivery of a site-specific anti-tumor medication is made easier by stem cells migrating to solid tumors and micro metastatic lesions. In order to circumvent the short half-lives of traditional chemotherapeutic medicines, stem cells can be genetically modified to stably express a range of anticancer medications. Also, the market for cancer stem cells is expanding as a result of the quick uptake of stem cells by medical professionals for tissue regeneration and as carriers of anti-cancer drugs. Medical specialists from all over the world reported positive results in treating tumors with stem cells. These factors are anticipated to boost market growth in the upcoming years.
The global cancer stem cells market share is segmented based on cancer forms, application, and region. By cancer forms, it is classified into breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and others. By application, it is classified into targeted cancerous stem cells and stem cell-based cancer therapy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in the cancer stem cells market report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.
The report offers a comprehensive analysis of the global cancer stem cells market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the cancer stem cells market growth. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.
Impact of Covid-19 on the Global Cancer Stem Cells Market Industry
The COVID-19 pandemic has impacted all stages of cancer treatment, including postponing cancer diagnosis and treatments and stopping clinical trials. To guarantee that patients continue to receive crucial care while reducing exposure to COVID-19 infection.Stem cell therapy and stem cell-derived tissue engineering models have garnered a lot of attention as a new treatment and research tool during COVID-19 pandemic.
Social distancing norms, closed borders, and production constraints, due to the pandemic, across various countries such as China, India, and the U.S. have affected the global cancer stem cells industry.
The ongoing COVID-19 epidemic and the subsequent lockdowns in numerous nations around the world are probably going to put pressure on the manufacturers to meet the demand for cancer cell therapies in the future.
Key Findings of the Study
- Based on cancer forms, the breast cancer sub-segment emerged as the global leader in 2021 and bladder sub-segment is anticipated to be the fastest growing sub-segment during the forecast period.
- Based on application, the stem cell-based cancer therapy sub-segment emerged as the global leader in 2021 and targeted cancerous stem cells sub-segment is predicted to show the fastest growth in the upcoming years.
- Based on region, the North America market registered the highest market share in 2021 and is projected to maintain the position during the forecast period.
Companies Mentioned
- Thermo Fisher Scientific Inc.
- AbbVie Inc.
- Miltenyi Biotec
- STEMCELL Technologies Inc.
- Merck KGaA
- Stemline Therapeutics, Inc.
- MacroGenics, Inc.
- Bionomics
- FUJIFILM Irvine Scientific.
- Lineage Cell Therapeutics, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
